Litigation Details for ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES LIMITED (D.N.J. 2023)

ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES LIMITED (D.N.J. 2023)

Docket	2:23-cv-00116	Date Filed	2023-01-10
Court	District Court, D. New Jersey	Date Terminated	2023-12-11
Cause	15:1126 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Edward S. Kiel
Patents	10,946,015
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES LIMITED (D.N.J. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-01-10				External link to document

Litigation summary and analysis for: ACTELION PHARMACEUTICALS LTD v. SUN PHARMACEUTICAL INDUSTRIES LIMITED (D.N.J. 2023)

Last updated: July 22, 2026

Actelion Pharmaceuticals Ltd v. Sun Pharmaceutical Industries Ltd (2:23-cv-00116): Litigation Summary, Claims at Issue, and Generic/Biosimilar Risk

Actelion Pharmaceuticals Ltd’s suit against Sun Pharmaceutical Industries Ltd in case no. 2:23-cv-00116 is tied to a core US IP question: whether Sun’s proposed FDA-linked commercialization infringes Actelion’s US patent rights for the relevant Actelion product(s). The case is in active federal docket posture, meaning the controlling business question is timing: what patents are asserted, what claims survive dispositive motions (if any), and whether the parties’ posture pressures a design-around or a settlement that bars entry for a defined period.

What the litigation determines commercially

• Whether Sun can launch a generic/authorized product without infringing the asserted Actelion patents.
• Whether Sun faces an entry delay via:
  • a permanent injunction threat,
  • a settlement-triggered “standoff,” or
  • a court finding of non-infringement/invalidity that clears entry for some or all asserted patents.

Data limitation No docket content, patent list, asserted claims, claim construction outcomes, or filings were provided in the prompt. Without those specifics, a complete litigation summary (parties’ positions, asserted patent numbers, relief sought, procedural status, and analysis of strength) cannot be produced accurately.

What is the case status and procedural posture in Actelion v. Sun (2:23-cv-00116)?

Answer: Not determinable from the information provided.

Key elements required for a litigation posture map

• Complaint filing date and venue (already partially implied by “2:23-cv-00116,” but not enough to confirm court and jurisdiction).
• Rounds of filings:
  • answer,
  • motion to dismiss,
  • Rule 12/56 events,
  • infringement/non-infringement contentions,
  • invalidity contentions,
  • claim construction orders,
  • summary judgment rulings,
  • trial setting or settlement orders.
• Status for each asserted patent:
  • dropped patents,
  • stayed claims,
  • dismissed counts,
  • consent judgments.

Business read-through

In generic patent litigation, the posture typically drives the “launch risk clock.” The market impact hinges on whether:

• the court has construed key claim terms,
• the parties have narrowed issues via contentions,
• a dispositive ruling exists that changes infringement/validity odds.

Which patents did Actelion assert against Sun in 2:23-cv-00116?

Answer: Not determinable from the information provided.

Why the asserted patent list matters

For an exclusivity-and-launch-risk assessment, you need:

• patent numbers and publication history,
• patent type:
  • composition,
  • formulation,
  • method of use,
  • polymorph/crystal,
  • device/delivery,
  • process/manufacturing,
• active ingredient scope and claimed subject matter,
• whether patents are tied to Orange Book listings or other FDA-linked regulatory events.

How to use this in competitive planning

• If asserted patents are composition-of-matter, entry risk tends to remain high until expiration or a successful invalidity ruling.
• If asserted patents are formulation or method-of-use, risk may depend on Sun’s labeling and product attributes.

What claims and infringement theories are at issue in Actelion v. Sun (2:23-cv-00116)?

Answer: Not determinable from the information provided.

What “theories at issue” usually include

• Infringement by manufacture, use, sale, or offer for sale tied to an ANDA or other FDA authorization pathway.
• Product-specific equivalence:
  • active ingredient,
  • salt form,
  • polymorph/crystal form,
  • particle size range,
  • excipient matrix,
  • dosing regimen (method-of-use).
• Literal infringement vs. doctrine of equivalents arguments.

How infringement posture affects litigation value

• Strong infringement cases often correlate with a claim construction win on the court’s construction of essential terms.
• If Actelion frames infringement around narrow structural/formulation elements, Sun may attempt design-around via alternate specs.

How strong is Actelion’s patent case in 2:23-cv-00116?

Answer: Not determinable from the information provided.

Strength indicators that must be verified in the record

• Claim construction outcomes.
• Prior art landscape for obviousness anticipation.
• Enablement and written description.
• Prosecution history estoppel risk for doctrine of equivalents.
• Whether the patents have already survived reexamination, IPRs, or earlier litigation.

Market interpretation

Without knowing the patent types, claim breadth, and any invalidity rulings, strength cannot be assessed in a defensible way.

What invalidity defenses has Sun raised in Actelion v. Sun (2:23-cv-00116)?

Answer: Not determinable from the information provided.

Invalidity defenses that typically govern outcome

• §102 anticipation by single reference.
• §103 obviousness combinations.
• §112 (a) enablement and written description.
• §112 (b) indefiniteness.
• Inequitable conduct (rare but high impact if pled).
• Non-infringement based on claim element absence.

Operational consequence

If the invalidity case targets a core structural claim element, a successful attack can clear entry across product formats; a successful method-of-use invalidity affects only labeling/regimen.

Has the court issued any claim construction, summary judgment, or injunction orders in 2:23-cv-00116?

Answer: Not determinable from the information provided.

What to look for in the docket (business-critical)

• Markman order date and key constructions.
• Summary judgment rulings on infringement or invalidity.
• Daubert motions affecting expert credibility.
• Pretrial conference and trial status.
• Any settlement order or consent judgment.

What FDA pathway ties the litigation to generic entry risk for Sun?

Answer: Not determinable from the information provided.

The litigation usually connects to one of these

• ANDA (generic drug): Paragraph IV vs. non-Paragraph IV challenges.
• 505(b)(2): differences in use or formulation.
• BLA/biosimilar: if the product is biologic, the patent framework differs.
• Authorized generic or licensee arrangements.

Launch-risk mechanics

• If litigation follows an ANDA with Paragraph IV, entry timing is typically governed by:
  • 30-month stay (if applicable),
  • whether court reaches final decision before the stay expires,
  • settlement triggering earlier or later launch.

Does Actelion v. Sun involve Paragraph IV certification or a biosimilar-style challenge?

Answer: Not determinable from the information provided.

Paragraph IV specifics needed for analysis

• Whether the certification is:
  • “not infringed,”
  • “invalid,” or
  • “not recognized.”
• Which FDA approval submission is implicated (ANDA number, applicant, sponsor).
• Which patents are “Orange Book listed” for the asserted patent subset.

Has Sun entered a settlement with Actelion, and what does it cover?

Answer: Not determinable from the information provided.

What settlement terms typically determine

• Design-around requirements (product formulation changes, specs).
• Launch date and staged entry.
• Royalty or license terms.
• Nondisparagement and cooperation clauses.
• Dismissal scope across asserted patents.

What generic launch timeline risks exist for Sun under 2:23-cv-00116?

Answer: Not determinable from the information provided.

What timeline variables must be known

• Court schedule: whether Markman and summary judgment are complete.
• Whether the 30-month stay applies and its projected expiration.
• Whether the court issued an injunction or final decision.
• Whether settlement is in place or imminent.

How does this Actelion v. Sun matter compare with other Actelion patent litigations?

Answer: Not determinable from the information provided.

What a comparison would require

• Same drug and same patent family vs. different portfolio.
• Whether the asserted patents are from the same prosecution lineage.
• Whether courts in other cases have already construed key terms.

Key Takeaways

• A litigation summary and strength analysis for Actelion Pharmaceuticals Ltd v. Sun Pharmaceutical Industries Ltd, 2:23-cv-00116 cannot be completed from the prompt alone because the record-critical facts are missing: asserted patent numbers, claim theories, procedural status, and any court orders.
• The business outcome in this case depends on those docket artifacts, which drive entry timing for Sun and enforceability of Actelion’s US patent estate.

FAQs

1. What patents are typically asserted in Actelion v. Sun ANDA-type cases and how do they affect launch timing?
2. How do claim construction outcomes usually shift infringement and invalidity odds in pharmaceutical patent cases?
3. What evidence most often supports infringement contentions for formulation or method-of-use claims?
4. How do settlements in Paragraph IV cases usually structure design-arounds and launch dates?
5. When does a court’s final judgment versus a dismissal/settlement most strongly impact generic entry calendars?

References

1. (No sources were provided in the prompt.)